1.2M
Downloads
914
Episodes
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Episodes
Friday Jun 21, 2024
Friday Jun 21, 2024
Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna
Tuesday Jun 18, 2024
Tuesday Jun 18, 2024
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Giant Cell Arteritis and Polymyalgia Rheumatica Update
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Pain in RA: Different Drugs for Different Mechanisms
Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
Top 3 Messages About JAK Inhibitor Safety
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
Select your GCA Therapy
Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.
Tuesday Jun 18, 2024
Tuesday Jun 18, 2024
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.
OP0046 Effect on SI joint structural lesions with ixekizumab
POS0058 Effect on SI joint structural lesions with bimekizumab
Does Telemonitoring in SpA Work?
Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
Treat to Target Outcomes in Early AxSpA
Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
Early Diagnosis of Axial Spondyloarthritis
Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria.
Imaging in Axial Spondyloarthritis
Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.
Tuesday Jun 18, 2024
Tuesday Jun 18, 2024
Does B Cell Depletion Matter?
Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.
3 Big Lupus Themes from EULAR 2024
Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.
POS0732
OP0255
Voclosporin and Steroids in Lupus Nephritis
Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Cognitive Function in Older Adults with Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
Does Withdrawing Steroids Increase Flares in SLE?
Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria.
Tapering Treatment for Lupus
Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus.
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity at Eular 2024 in Vienna, Austria.
We've Got to Talk about CAR T cells
Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.
Tuesday Jun 18, 2024
Tuesday Jun 18, 2024
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
PsA Treatment: is Earlier Better?
Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.
Transition from Psoriasis to PsA: Can we Prevent It?
Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.
Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA
Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.
PsA Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria.
Axial & Psoriatic Disease
Dr. Peter Nash at Eular 2024 in Vienna, Austria.
Difficult to Treat Psoriatic Arthritis
Dr. Peter Nash reports at Eular 2024 in Vienna, Austria.
Predictors of Treatment Response in Psoriatic Arthritis
Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:
POS 0990
POS 0992
POS 0266
Prevention of Psoriatic Arthritis
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
Tuesday Jun 18, 2024
Tuesday Jun 18, 2024
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.
A Step Closer to Identifying Phenotypes of RA ILD
Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria.
Pain in RA: Different Drugs for Different Mechanisms
Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.
Top 3 Messages About JAK Inhibitor Safety
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
Artificial Intelligence Detection of CPPD on Hand Radiographs
Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria.
Cognitive Function in Older Adults with Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
Difficult-to-treat Rheumatoid Arthritis Validation of the EULAR Definition
Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria.
DMARDs and Herpes Zoster Vaccination To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
Inspirations About RA-ILD
Dr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria.
Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA
Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.
Digital Rheumatology
Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.
Drug-resistant RA Does Blinatumomab BiTE?
Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.
Monday Jun 17, 2024
Monday Jun 17, 2024
Axial & Psoriatic Disease
Dr. Peter Nash at Eular 2024 in Vienna, Austria.
Difficult to Treat Psoriatic Arthritis
Dr. Peter Nash reports at Eular 2024 in Vienna, Austria.
Predictors of Treatment Response in Psoriatic Arthritis
Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:
POS 0990
POS 0992
POS 0266
Prevention of Psoriatic Arthritis
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA
Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.
Digital Rheumatology
Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.
Drug-resistant RA Does Blinatumomab BiTE?
Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.
Early Diagnosis of Axial Spondyloarthritis
Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria.
Imaging in Axial Spondyloarthritis
Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.
Monday Jun 17, 2024
Monday Jun 17, 2024
Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:
POS 0990
POS 0992
POS 0266
Monday Jun 17, 2024
Monday Jun 17, 2024
Moderated by Dr. Jack Cush and featuring Dr. Aurelie Najm and Dr. David Liew Recorded June 15, 2024
Monday Jun 17, 2024
Monday Jun 17, 2024
Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria.